Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 19/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20833579 | 0.90 | TACR1 (0.40) | MRGPRX4LRRK2 | |
| SCHEMBL22066298 | 0.90 | TACR1 (0.42) | MRGPRX4LRRK2 | |
| SCHEMBL18973556 | 0.89 | MRGPRX4 (0.51) | MRGPRX4 | |
| SCHEMBL22065045 | 0.89 | POLB (0.42) | MRGPRX4 | |
| SCHEMBL22065044 | 0.87 | BTN3A1 (0.43) | MRGPRX4 | |
| SCHEMBL22065648 | 0.87 | BTN3A1 (0.39) | MRGPRX4 | |
| SCHEMBL22066301 | 0.86 | MRGPRX4 (0.43) | MRGPRX4LRRK2 | |
| SCHEMBL20833582 | 0.85 | BTN3A1 (0.43) | MRGPRX4 | |
| SCHEMBL22066302 | 0.85 | BTN3A1 (0.39) | MRGPRX4 | |
| SCHEMBL22066001 | 0.85 | MRGPRX4 (0.43) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402962-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2022-12-22 | — | — | US | disclosed |
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | NuCana plc (GB) | 2020-06-11 | — | — | US | disclosed |
| WO-2019053476-A1 | FLOXURIDINE SYNTHESIS | NuCana plc (GB) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181186-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PPA1, PPIP5K2, TYMP | MRGPRX4 4643/4885LRRK2 3683/4885 |
| US-20220402962-A1 | SYNTHESIS OF PHOSPHATE DERIVATIVES | PNP, NTPCR, TYMP | MRGPRX4 4449/4885LRRK2 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.